Overview

A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled portion to evaluate the efficacy and safety of OMP-59R5 in combination with nab-paclitaxel and gemcitabine in subjects with previously untreated stage IV pancreatic cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

OncoMed Pharmaceuticals, Inc.

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel